.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,685,444

« Back to Dashboard

Claims for Patent: 8,685,444

Title:Sequestering subunit and related compositions and methods
Abstract: A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.
Inventor(s): Boehm; Garth (Westfield, NJ)
Assignee: Alpharma Pharmaceuticals LLC (Bridgewater, NJ)
Application Number:12/766,488
Patent Claims: 1. A pharmaceutical composition comprising: a. a sequestering subunit comprising: i. a naltrexone core comprising naltrexone on a substrate; and, ii. a coating comprising a hydrophobic material and a surfactant covering the naltrexone core, wherein the ratio of hydrophobic material to surfactant in the coating is about 30:1; and, b. an overcoat comprising an opioid agonist covering the sequestering subunit.

2. The pharmaceutical composition of claim 1 wherein the hydrophobic material is a copolymer of acrylic acid and methacrylic acid.

3. The pharmaceutical composition of claim 1 wherein the hydrophobic material is Eudragit RSPO.

4. The pharmaceutical composition of claim 1 wherein the surfactant is sodium lauryl sulphate.

5. The pharmaceutical composition of claim 1 wherein the hydrophobic material is Eudragit RSPO and the surfactant is sodium lauryl sulphate.

6. The pharmaceutical composition of claim 1 wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, oxycodone, and hydrocodone.

7. The pharmaceutical composition of claim 6 wherein the opioid agonist is morphine.

8. The pharmaceutical composition of claim 7 wherein the hydrophobic material is Eudragit RSPO and the surfactant is sodium lauryl sulphate.

9. The pharmaceutical composition of claim 1 wherein the substrate is a sugar sphere.

10. The pharmaceutical composition of claim 9 wherein the hydrophobic material is a copolymer of acrylic acid and methacrylic acid.

11. The pharmaceutical composition of claim 9 wherein the hydrophobic material is Eudragit RSPO.

12. The pharmaceutical composition of claim 9 wherein the surfactant is sodium lauryl sulphate.

13. The pharmaceutical composition of claim 9 wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, oxycodone, and hydrocodone.

14. The pharmaceutical composition of claim 13 wherein the opioid agonist is morphine.

15. The pharmaceutical composition of claim 14 wherein the hydrophobic material is Eudragit RSPO and the surfactant is sodium lauryl sulphate.

16. The pharmaceutical composition of claim 1 wherein the blocking agent prevents the release of at least about 99% of the naltrexone from the sequestering subunit in the gastrointestinal tract for at least about 12 hours.

17. The pharmaceutical composition of claim 16 wherein the hydrophobic material is Eudragit RSPO and the surfactant is sodium lauryl sulphate.

18. The pharmaceutical composition of claim 17 wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, oxycodone, and hydrocodone.

19. The pharmaceutical composition of claim 18 wherein the opioid agonist is morphine.

20. The pharmaceutical composition of claim 1 wherein the blocking agent prevents the release of at least about 95% of the naltrexone from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours.

21. The pharmaceutical composition of claim 20 wherein the hydrophobic material is Eudragit RSPO and the surfactant is sodium lauryl sulphate.

22. The pharmaceutical composition of claim 1 wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, oxycodone, and hydrocodone.

23. The pharmaceutical composition of claim 22 wherein the opioid agonist is morphine.

24. The pharmaceutical composition of claim 1 wherein the blocking agent prevents the release of at least about 99% of the naltrexone from the sequestering subunit in the gastrointestinal tract for at least about 12 hours and prevents the release of at least about 95% of the naltrexone from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours.

25. The pharmaceutical composition of claim 24 wherein the hydrophobic material is Eudragit RSPO and the surfactant is sodium lauryl sulphate.

26. The pharmaceutical composition of claim 25 wherein the opioid agonist is selected from the group consisting of morphine, hydromorphone, oxycodone, and hydrocodone.

27. The pharmaceutical composition of claim 26 wherein the opioid agonist is morphine.

28. The pharmaceutical composition of any one of claim 16, 20, or 24 wherein release of naltrexone in the gastrointestinal tract is determined by dissolution testing conducted according to USP26 Chapter <711>using Apparatus 1 (baskets) at 50 rpm, 500 mL of water, 37.degree. C. and high-performance liquid chromatography assay.

29. The pharmaceutical composition of any one of claim 19, 23, or 27 wherein release of naltrexone in the gastrointestinal tract is determined by dissolution testing conducted according to USP26 Chapter <711>using Apparatus 1 (baskets) at 50 rpm, 500 mL of water, 37.degree. C. and high-performance liquid chromatography assay.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc